Vintafolide

From WikiMD.org
Jump to navigation Jump to search

Vintafolide

Vintafolide (pronunciation: vin-ta-fo-lide) is a small molecule drug conjugate that targets cancer cells. It was developed by Endocyte and Merck & Co. for the treatment of various types of cancer, including ovarian cancer and lung cancer.

Etymology

The name "Vintafolide" is derived from the components of the drug: "vin" for vinblastine, a chemotherapy drug; "ta" for targeting agent; and "folide" for folic acid, which the drug uses to target cancer cells.

Mechanism of Action

Vintafolide works by binding to the folate receptor, which is overexpressed in many types of cancer cells. The drug is then internalized by the cell, where it releases the chemotherapy drug vinblastine to kill the cell.

Clinical Trials

Vintafolide has been tested in several clinical trials for the treatment of ovarian cancer and lung cancer. However, in 2014, the drug failed a phase III clinical trial for ovarian cancer, leading Merck & Co. to discontinue its development.

Related Terms

  • Vinblastine: A chemotherapy drug used in the treatment of various types of cancer.
  • Folate receptor: A cell surface receptor that binds folic acid and is overexpressed in many types of cancer cells.
  • Ovarian cancer: A type of cancer that begins in the ovaries.
  • Lung cancer: A type of cancer that begins in the lungs.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski